| Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma SS Neelapu, FL Locke, NL Bartlett, LJ Lekakis, DB Miklos, CA Jacobson, ... New England Journal of Medicine 377 (26), 2531-2544, 2017 | 4765 | 2017 |
| Origins of circulating endothelial cells and endothelial outgrowth from blood Y Lin, DJ Weisdorf, A Solovey, RP Hebbel The Journal of clinical investigation 105 (1), 71-77, 2000 | 2093 | 2000 |
| Chimeric antigen receptor T-cell therapy—assessment and management of toxicities SS Neelapu, S Tummala, P Kebriaei, W Wierda, C Gutierrez, FL Locke, ... Nature reviews Clinical oncology 15 (1), 47-62, 2018 | 2056 | 2018 |
| Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial FL Locke, A Ghobadi, CA Jacobson, DB Miklos, LJ Lekakis, OO Oluwole, ... The lancet oncology 20 (1), 31-42, 2019 | 1865 | 2019 |
| Idecabtagene vicleucel in relapsed and refractory multiple myeloma NC Munshi, LD Anderson Jr, N Shah, D Madduri, J Berdeja, S Lonial, ... New England Journal of Medicine 384 (8), 705-716, 2021 | 1437 | 2021 |
| Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma N Raje, J Berdeja, YI Lin, D Siegel, S Jagannath, D Madduri, M Liedtke, ... New England Journal of Medicine 380 (18), 1726-1737, 2019 | 1421 | 2019 |
| Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1 … JG Berdeja, D Madduri, SZ Usmani, A Jakubowiak, M Agha, AD Cohen, ... The Lancet 398 (10297), 314-324, 2021 | 888 | 2021 |
| Circulating activated endothelial cells in sickle cell anemia A Solovey, Y Lin, P Browne, S Choong, E Wayner, RP Hebbel New England Journal of Medicine 337 (22), 1584-1590, 1997 | 811 | 1997 |
| Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013 JR Mikhael, D Dingli, V Roy, CB Reeder, FK Buadi, SR Hayman, ... Mayo Clinic Proceedings 88 (4), 360-376, 2013 | 692 | 2013 |
| Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium LJ Nastoupil, MD Jain, L Feng, JY Spiegel, A Ghobadi, Y Lin, S Dahiya, ... Journal of Clinical Oncology 38 (27), 3119, 2020 | 590 | 2020 |
| Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL W Ding, BR LaPlant, TG Call, SA Parikh, JF Leis, R He, TD Shanafelt, ... Blood, The Journal of the American Society of Hematology 129 (26), 3419-3427, 2017 | 414 | 2017 |
| KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study BD Shah, A Ghobadi, OO Oluwole, AC Logan, N Boissel, RD Cassaday, ... The Lancet 398 (10299), 491-502, 2021 | 412 | 2021 |
| Immunosuppressive CD14+HLA‐DRlow/− monocytes in prostate cancer S Vuk‐Pavlović, PA Bulur, YI Lin, R Qin, CL Szumlanski, X Zhao, AB Dietz The Prostate 70 (4), 443-455, 2010 | 320 | 2010 |
| Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death E Muchtar, MA Gertz, SK Kumar, MQ Lacy, D Dingli, FK Buadi, M Grogan, ... Blood, The Journal of the American Society of Hematology 129 (15), 2111-2119, 2017 | 293 | 2017 |
| Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma FL Locke, JM Rossi, SS Neelapu, CA Jacobson, DB Miklos, A Ghobadi, ... Blood advances 4 (19), 4898-4911, 2020 | 274 | 2020 |
| Immunosuppressive CD14+HLA-DRlow/− monocytes in B-cell non-Hodgkin lymphoma Y Lin, MP Gustafson, PA Bulur, DA Gastineau, TE Witzig, AB Dietz Blood, The Journal of the American Society of Hematology 117 (3), 872-881, 2011 | 274 | 2011 |
| Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties JC Rodrigues, GC Gonzalez, L Zhang, G Ibrahim, JJ Kelly, MP Gustafson, ... Neuro-oncology 12 (4), 351-365, 2010 | 266 | 2010 |
| Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone MP Gustafson, Y Lin, KC New, PA Bulur, BP O'Neill, DA Gastineau, ... Neuro-oncology 12 (7), 631-644, 2010 | 251 | 2010 |
| Ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up T Martin, SZ Usmani, JG Berdeja, M Agha, AD Cohen, P Hari, D Avigan, ... Journal of Clinical Oncology 41 (6), 1265, 2023 | 245 | 2023 |
| Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis TV Kourelis, SK Kumar, MA Gertz, MQ Lacy, FK Buadi, SR Hayman, ... Journal of clinical oncology 31 (34), 4319, 2013 | 241 | 2013 |
Angela DispenzieriMayo ClinicBestätigte E-Mail-Adresse bei mayo.edu
